Results 121 to 130 of about 5,558,618 (260)

Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland. [PDF]

Background: Toxicity or treatment failure related to drug-drug interactions (DDIs) are known to significantly affect morbidity and hospitalization rates.
Le Pogam, Marie-Annick, Le Pogam, M.A., Coumau, Claire, Gaspar, F., Terrier, Jean, Gaspar, Frederic, Csajka, C., Schulthess-Lisibach, Angela, Schulthess-Lisibach, A., Csajka, Chantal, Lutters, M., Coumau, C., Terrier, J., Lutters, Monika   +13 more
core   +2 more sources

Prevalence of Potential Drug-drug Interactions among Psychiatric Patients at Psychiatry Hospital in Sulaimani City

Al-Mustansiriyah Journal of Pharmaceutical Sciences
Background: Clinically significant drug-drug interactions can be defined as events in which the pharmacodynamics or pharmacokinetic characteristics of a drug are modified by coadministration of a second drug to the patient’s medication protocol, which ...
Raz Muhammed HamaSalih, Rebwar Ghareeb Hama, Sabir Hamid, Pavel Jalal Hussein, Sham Nawshirwan Salh   +4 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

National drug-related public expenditure online resource.

, 2021
This is the first set of national profiles that the EMCDDA has produced on drug-related public expenditure. The profiles are based on the sections on public expenditure provided by the 27 EU Member States, Croatia, Turkey and Norway in the national ...

core  

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data [PDF]

Nina L Wittwer,1,2 Christoph R Meier,1– 3 Carola A Huber,4 Julie D Moser,1 Henriette E Meyer zu Schwabedissen,5 Samuel S Allemann,6,* Cornelia Schneider1,2,* 1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,
Huber CA, Meier CR, Moser JD, Schneider C, Meyer zu Schwabedissen HE, Allemann SS, Wittwer NL   +6 more
core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

The Development and Evaluation of Triage Algorithms for Early Discovery of Adverse Drug Interactions

, 2013
Background Around 20 % of all adverse drug reactions (ADRs) are due to drug interactions. Some of these will only be detected in the postmarketing setting.
Edwards, Ralph I.,, Caster, Ola,, Strandell, Johanna,, Noren, Niklas G.,, Hopstadius, Johan,   +4 more
core   +1 more source

Survey on Polypharmacy and Drug-Drug Interactions Among Elderly People with Cardiovascular Diseases at Yekatit 12 Hospital, Addis Ababa, Ethiopia

Integrated Pharmacy Research and Practice, 2020
Yelbeneh Abayneh Assefa,1 Ansha Kedir,1 Wubayehu Kahaliw2 1Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 2Department of Pharmacology, School of Pharmacy ...
Assefa YA, Kedir A, Kahaliw W
doaj  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source